Weight Loss Injections for Prediabetes: What to Know Before You Decide

What the clinical evidence actually shows for people with prediabetes

Prediabetes sits in the gap between normal blood sugar and a type 2 diabetes diagnosis. The core risk is progression, but it is not inevitable, and weight loss is the single most powerful lever most people can pull. A question our prescribers hear most weeks is whether a GLP-1 injection can help specifically with that risk, and the honest answer is that the evidence is encouraging, though the medicines are not licensed as a prediabetes treatment in their own right.

The SURMOUNT-1 trial of tirzepatide, published in the New England Journal of Medicine, enrolled adults with obesity and weight-related conditions, a large proportion had prediabetes at the start. At the highest dose after 72 weeks, participants lost an average of around 20–21% of body weight, and a significant number who entered with prediabetes had returned to normal glucose levels by the end. The weight loss drove the metabolic change, not a direct blood-sugar mechanism at the weight-management dose. For semaglutide (Wegovy), the STEP 1 trial showed similar patterns: meaningful average weight reduction accompanied by improvements in fasting glucose and related markers.

What this means in practice is that these medicines can be genuinely relevant if you have prediabetes and meet the prescribing criteria. They do not treat the prediabetes directly; they treat the weight, and the metabolic picture often follows. Any prescriber will consider this alongside your current HbA1c, medications, and wider health before approving treatment. You can read more about how these medicines are used in metabolic and glucose-related contexts here.

Who is likely to be suitable (and where the limits sit

The licensed eligibility criteria for both Mounjaro and Wegovy centre on BMI) at least 30, or at least 27 if you have one or more weight-related health conditions. Prediabetes counts as a qualifying condition at the 27-threshold, which means some people who might not otherwise meet BMI requirements can still be considered. The NICE appraisal of tirzepatide (TA1026) lays out how UK commissioning criteria reflect this logic, with adjusted BMI thresholds also applying for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds.

That said, BMI is not the whole story. A prescriber will also look at your medication list, any history of pancreatitis, thyroid conditions, and a range of other factors before deciding whether treatment is appropriate. People with a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not use these medicines. If you are under 18, these medicines are not licensed for you. If you are pregnant, breastfeeding, or hoping to conceive in the near future, they are not recommended, this is not a grey area, and you should speak to your GP about safe alternatives during those periods.

The full list of situations where these medicines are not suitable is worth reading before you start a consultation, so you arrive with a clear picture of your own circumstances.

The decision that sits with you, and the one that sits with a prescriber

This is a SK3 page because the real shape of this topic is a decision. You are weighing whether to pursue treatment, and you need enough information to make that call thoughtfully. Here is how to think about the two sides.

What you can decide: whether weight management treatment aligns with what you want for your health, and whether the private route makes sense given your circumstances. If you have prediabetes and have already tried sustained dietary and activity changes without seeing the metabolic shift you were hoping for, that context matters and is worth raising in a consultation. You can explore the broader range of weight loss treatments available through our service to get a sense of what the options look like before committing to anything.

What only a prescriber can decide: whether a specific medicine is clinically appropriate for you, at what dose to start, and how your prediabetes and any other conditions affect that picture. Titration (the step-by-step dose increases that happen over weeks and months) is guided by your clinical team, not a self-service process. The question of which injection suits prediabetes best also has a clinical dimension that depends on your individual profile, and that is genuinely a conversation to have in assessment rather than something a webpage can resolve.

Side effects are worth knowing about before you decide. GI symptoms (nausea, loose stools, sluggish digestion, sometimes reflux) are the most commonly reported, typically peaking in the early weeks and settling as your body adjusts. On rare occasions, more serious effects including pancreatitis can occur; the MHRA issued specific guidance on this in January 2026, flagging severe or persistent stomach pain that radiates to the back as a reason to seek urgent medical help. The MHRA's Yellow Card scheme allows anyone to report side effects directly. A full overview of what weight loss injections involve day to day covers the practical detail.

How prediabetes interacts with type 1 and type 2 diabetes scenarios

Prediabetes is not type 1 or type 2 diabetes, and the distinction matters for how these medicines fit in. Wegovy and Mounjaro are licensed for weight management, including in people with type 2 diabetes (Mounjaro also carries a type 2 diabetes licence in its own right). They are not licensed for type 1 diabetes, and the evidence base for that population is limited and complex. If you have type 1 alongside excess weight, that requires specialist input rather than a standard private weight-loss pathway, our page on type 1 diabetes and weight loss injections covers the nuance honestly.

For prediabetes specifically, the NHS pathway for these medicines is still largely restricted to people who already have type 2 diabetes or meet the phased NICE rollout criteria, so many people with prediabetes are not currently eligible through their GP. That makes the private route the realistic option for a lot of people in this situation. Understanding what private treatment costs in the UK is a practical part of that picture. A prescriber through our service reviews your consultation the same day (a real clinician, not software) and your prediabetes diagnosis is part of what they consider.